Thank you, Chuck, and good afternoon. On my behalf as well. And welcome to Orion Corporation 2025 webcast.
I'll start with some highlights from our first quarter.
I'm happy to tell you that all our four businesses have generated growth. And the fifth one, Fermion didn’t grow, but I will explain a bit about that later on.
Also, our geographic expansion and R&D capabilities program is progressing, and we have opened an R&D site in Cambridge with the purpose of strengthening our pharmaceutical development for biologics. Also, there is a new key project in our clinical pipeline. This Phase III trial focuses on Levosimendan for pulmonary hypertension in a specific patient segment, and it is being conducted by Tenax Therapeutics, Inc.
in the United States.
On financials. The first quarter was excellent. Net sales grew 14.9% and our operating profit increased by 39.1%. And also, the operating profit margin improved from last year's first quarter.
Cash flow decreased to some extent, mainly due to the timing of royalty payments and some milestone payments between quarters. Our net sales bridge looks a bit different than previously. If you remember earlier, we had net sales based on some of our biggest products, and now we have divided our net sales picture based on our divisions.
Now, it's easier to follow up how each division is doing and which divisions are creating more or less growth. Since all three human divisions and Animal Health are creating growth. So, innovative medicines. Uh, €1,440.4 million in quarter one for branded products, €6.8 million, and generics, €1 million. Animal Health showed €3.3 million of growth. Fermion, as I already said, was not developing positively.
But let's remember that this is only external sales. And then there are some internal transactions between Orion's other operations, which are very marginal here, amounting to 100 million.
But all this ended up in €354.6 million of net sales in quarter one. Operating profit remained mostly consistent with previous figures. But we've made it a bit clearer with our texts.
So, the first column here, €13.7 million, points to the change in volumes. So this shows the euros that the volume increase has generated, leading to significant growth. Then the second one includes the change that comes from changes in prices, costs, and product mix. So, a slight decrease there by 5.6 million.
And then the third one is the effect of exchange rate changes on our gross margin from royalties.
Clearly, the biggest contributor here is the fifth point, which is milestones compared to the last year's first quarter. A bit of a decrease there and then other operating income and expenses. And then at number seven here in column seven, you can see the fixed costs, which are mainly sales and marketing costs, in quarter one. And all this ended up close to 78 million in operating profit during the first quarter. Now I turn to Innovative Medicines, 70.4% growth here, which has almost created 100 million in sales in the first quarter. So we haven't yet exceeded the 100 million per quarter mark. And here on the right-hand side, you can see a clear phenomenon of a back-end loaded financial year in innovative medicines. You can see how the year ended in quarter 4 2024 with 152 million, actually. And now we started with 92 in the first quarter.
And then, but you can clearly see that there is significant growth compared to the first quarter.
So no worries if there is a change downwards from the last quarter of the previous year.
We've explained earlier that the royalty rate increases significantly during the year as certain sales thresholds in euros are exceeded. Also, you can see here that the tablets that we deliver to Bayer reached an all-time high number. €38 million.
Branded products. Almost 10% growth.
And here you can also see a different type of split.
Here we talk about CNS, not specific products.
And we can see that the respiratory business is clearly the biggest one here. And the CNS business, back on a growth track, represents 30% of the branded products.
And the entire Easyhaler portfolio grew by 8%. And the combination of budesonide-formoterol continued strong growth with almost 15%.
And after a long time, Entacapone has reappeared on the top ten list.
But CNS sales grew 5.7%, partly and mainly because of entacapone sales in Japan, but also because of some minor new products that are in that portfolio. Generics and consumer health. Almost 1% growth. A wonderful achievement in that portfolio.
And here, the geographical split shows that Finland is the biggest single market for generics and consumer health. Scandinavia is the second biggest region, followed by Eastern Europe. And to reach this almost 1% growth. One of the main drivers was actually Scandinavia.
This time, we were able to supply products that other companies were not able to supply in certain Scandinavian markets, which again shows and proves the excellent service level that we have in our generics business.
Animal health showed a strong growth with a 10% increase.
It was a bit lower in sales, although slower than last year, but still at a very good level in general in the animal health business.
And then Fermion, as I already mentioned, declined.
But let's remember this is only external sales, and a majority of the capacity is now bound to our internal own products.
Top ten products.
There are pluses and minuses. Plus 85% for Nubeqa; Easyhaler 8%. As I already said, Entacapone products showed a 6% increase. Japan is contributing to this growth as expected after the repatriation from Novartis.
The minus on Dexdomitor and Domitor animal health sedatives is mainly due to the timing of shipments to our partners. So no, no worries there. There's been a lot of fluctuation between the quarters lately, and the Divina series, meaning mainly our estradiol gel product.
30% growth.
I think that's after Nubeqa.
That's actually our fastest growing product currently.
Burana more or less at par with the previous year's first quarter. This is very normal. It's plus or minus 1 to 2% depending on the finish. Sales of Simdax and Dexdor portfolios are sliding down due to generic competition. Decision Trexan again, shipments from one quarter to another. And then a new entrant to this list is the Quetiapine products from our generic portfolio. It has climbed up to our top ten, mainly because Dexdor is going down, and I guess we'll see some of the biggest generics actually entering this list as generics. Dexdor and Simdax are sliding down, but we do sell Quetiapine in all the Nordic countries. And innovative medicines.
Almost 30% of the revenues come from branded products, 22% from branded products, and 37% from generics. In the clinical pipeline, we have two Phase III projects ongoing with Nubeqa, which is very familiar to this audience. Aeronaut is already in the registration phase globally.
The other step in phase three includes two projects ongoing with Open Orpha Omaha 1 and Omaha 2 for a different segment or phase of prostate cancer. And then one phase two study ongoing with Vessel Start, which is a continuation from the phase two study that we used to design the Phase III. The Phase III studies that we mentioned above include the Cupid's study and Odeum 212. And as I last time told, we are expanding that Phase I this year so that we have enough data to choose the right doses for the Phase II study.
In the Tasipimidine study or program, we continue with phase two. This year we started with a very small phase 2A, and now we are expanding to the full-blown phase two.
Then the new entrant, which we could call TNX 103 as Tenax calls it. This is an oral levosimendan. So the molecule is the same as in the Simdax product. But that's an IV product.
This is an oral formulation, and it's used for treating pulmonary hypertension in patients with heart failure and an ejection fraction. Ejection rejection. Fraction of a certain magnitude, which in this case means a normal fraction. But these patients suffer from pulmonary hypertension. And this is quite a long story about why this appeared in our clinical pipeline.
And maybe you do have questions regarding this, so I may shortly and briefly summarize the story.
Already more than ten years ago, we made a deal with a company called Fixus, which at that time was an American company. They wanted to develop oral levosimendan for low cardiac output syndrome.
Unfortunately, that study failed. We still continued a collaboration with the same people, now in the company called Tenax, and they managed and succeeded in getting finance for this program with levosimendan for this indication. And this came public in March this year. So this was the right time to bring it public here in our pipeline as this is our molecule and partner agreement. Like we have partner agreements with other companies such as Bayer, Merck, and also smaller companies. Then to a very different subject, sustainability and highlights from 2024. This was a huge job and I thank the team for this.
I think all the companies have been working a lot to fulfill these European requirements. The pharmaceutical industry is all about patient safety and quality, and in 2024 we conducted 258 audits.
Imagine that this means every week, there are approximately five audits.
And if you count out, you know, Christmas and Easter and all the other holidays and bank holidays, it means that every week there are many groups of people from Orion visiting other companies, you know, checking how those factories are from the quality perspective. And I think this also tells a lot about our external suppliers, highlighting the number of suppliers we have. Then, of course, environment is another very important aspect.
And here we've been able to reduce Scope 1 and Scope 2 emissions by 21% during 2024.
And we have a very ambitious target, which is explained in our report, set to achieve by the year 2030. Safety of our colleagues is also very, very important both in our operations and in general for all of our colleagues, whether they are working in sales, R&D, or operations. To that purpose, we conduct safety discussions and safety sessions where we discuss topics in every other management meeting or team meeting. And you can see here that 72% of our line managers held this kind of safety session with their team every month. Of course, there might be teams that hold those more often, and maybe teams that hold them a bit less frequently. Our code of conduct was renewed last year, and here you can see that 94% of Orion's employees have had the code of conduct training last year. And of course, our target is 100%. And in most of the functions, it is 100%. But everybody understands that in a big organization, new people are constantly coming in and others are leaving. So, there are of course some limitations to reaching a full 100%. But that's definitely our aim because that's implemented in our onboarding process. Whenever anybody starts at Orion, they need to complete the code of conduct training from here on. Our outlook remains the same for this year as we've stated in February. So it's from €1,550 million to €1,650 million regarding net sales and €350 million to €450 million regarding operating profit. We will hold a Capital Markets Day in Helsinki on the 22nd of May.
So I warmly welcome all of you to attend our Capital Markets Day, where we will share more light and wider and deeper information on each of our divisions, their product portfolios, current portfolios, their visions, and also current operations. And here you can see other upcoming events for the rest of this year: the half-year financial report in mid-July, and then, finally, October, the first nine months.
At this point, I thank you for your attention, and I think it's time for questions. So I welcome our CFO, Rene Lindell, on stage to talk. I will join as well.